I-O™ Ralimetinib Mesylate (CAT#: ITS-0622-YT324)

Ralimetinib Mesylate (LY2228820) is a potent and selective, ATP-competitive inhibitor of p38 MAPK α/β (IC₅₀ = 5.3 and 3.2 nM, respectively) with anti-inflammatory and anti-neoplastic activities. It selectively inhibits phosphorylation of MK2 (Thr334), with no effect on phosphorylation of p38α MAPK, JNK, ERK1/2, c-Jun, ATF2, or c-Myc. I-O™ Ralimetinib Mesylate is supplied as the dimesylate salt of the molecule.

Cell Expansion, Maintenance

1 mg

5-[2-(1,1-dimethylethyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)-3H-imidazo[4,5-b]pyridin2-amine, dimethanesulfonate

Cancer Cells and Cell Lines, Hematopoietic Stem and Progenitor Cells

Human, Mouse, Rat, Non-Human Primate, Other

p38 MAPK

p38 MAPK α/β

p38 MAPK Inhibitor

Immunology

Restrictions for research use only. Intended for use by laboratory professionals.